to your health
The “New Ozempic” falls short.
If you wondered why the NVO stock (see above) was down almost 20% yesterday, look no further. “[Its] experimental diabetes and weight-loss drug CagriSema fell short of expectations. The drug did not achieve the projected 25% average weight loss anticipated […]